Gritstone bio, Inc. Sued for Securities Law Violations - Contact The Rosen Law Firm Before August 6, 2024 to Discuss Your Rights - GRTS
NEW YORK, July 3, 2024 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritstone bio, Inc. (NASDAQ: GRTS) between March 9, 2023 and February 29, 2024, both dates inclusive (the "Class Period"), of the important August 6, 2024 lead plaintiff deadline.
So what: If you purchased Gritstone securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Gritstone class action, go to https://rosenlegal.com/submit-form/?case_id=25945mailto:or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 6, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Gritstone would be unable to launch the Phase 2b CORAL Study, a study comparing Gritstone's COVID-19 vaccine candidate with an approved COVID-19 vaccine, in the timeframe it had represented to investors; (2) the foregoing would impair Gritstone's ability to obtain external funding in connection with the Phase 2b CORAL Study, thereby negatively affecting Gritstone's ability to maintain its balance sheet and cash position; (3) accordingly, Gritstone overstated its ability to successfully develop and commercialize its products; and (4) as a result, Gritstone's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Gritstone class action, go to https://rosenlegal.com/submit-form/?case_id=25945mailto:or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/gritstone-bio-inc-sued-for-securities-law-violations--contact-the-rosen-law-firm-before-august-6-2024-to-discuss-your-rights---grts-302189315.html
SOURCE THE ROSEN LAW FIRM, P. A.
Ausgewählte Hebelprodukte auf Gritstone Oncology
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Gritstone Oncology
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Gritstone Oncology Aktie News
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Gritstone Oncology Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Gritstone Oncology nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 07.03.19 | Gritstone Oncology Buy | H.C. Wainwright & Co. | |
| 23.10.18 | Gritstone Oncology Buy | BTIG Research |
